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Abstract
Background: The triple burden of COVID-19, tuberculosis and human immunodeficiency virus is one of the major
global health challenges of the twenty-first century. In high burden HIV/TB countries, the spread of COVID-19
among people living with HIV is a well-founded concern. A thorough understanding of HIV/TB and COVID-19
pandemics is important as the three diseases interact. This may clarify HIV/TB/COVID-19 as a newly related field.
However, several gaps remain in the knowledge of the burden of COVID-19 on patients with TB and HIV. This study
was conducted to review different studies on SARS-CoV, MERS-CoV or COVID-19 associated with HIV/TB co-infection
or only TB, to understand the interactions between HIV, TB and COVID-19 and its implications on the burden of the
COVID-19 among HIV/TB co-infected or TB patients, screening algorithm and clinical management.
Methods: We conducted an electronic search of potentially eligible studies published in English in the Cochrane
Controlled Register of Trials, PubMed, Medrxiv, Google scholar and Clinical Trials Registry databases. We included
case studies, case series and observational studies published between January, 2002 and July, 2020 in which SARS-
CoV, MERS-CoV and COVID-19 co-infected to HIV/TB or TB in adults. We screened titles, abstracts and full articles for
eligibility. Descriptive and meta-analysis were done and results have been presented in graphs and tables.
Results: After removing 95 duplicates, 58 out of 437 articles were assessed for eligibility, of which 14 studies were
included for descriptive analysis and seven studies were included in the meta-analysis. Compared to the descriptive
analysis, the meta-analysis showed strong evidence that current TB exposure was high-risk COVID-19 group (OR
1.67, 95% CI 1.06–2.65, P = 0.03). The pooled of COVID-19/TB severity rate increased from OR 4.50 (95% CI 1.12–
18.10, P = 0.03), the recovery rate was high among COVID-19 compared to COVID-19/TB irrespective of HIV status
(OR 2.23, 95% CI 1.83–2.74, P < 0.001) and the mortality was reduced among non-TB group (P < 0.001).
Conclusion: In summary, TB was a risk factor for COVID-19 both in terms of severity and mortality irrespective of
HIV status. Structured diagnostic algorithms and clinical management are suggested to improve COVID-19/HIV/TB
or COVID-19/TB co-infections outcomes.
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Background
The triple burden of COVID-19, tuberculosis (TB) and
human immunodeficiency virus (HIV) is one of the
major and persistent global health challenges of the
twenty-first century. In the last two decades, three major
coronavirus epidemics have been reported worldwide.
Those epidemics are caused by different agents: severe
acute respiratory syndrome coronavirus (SARS-CoV) in
2002, Middle East respiratory syndrome coronavirus
(MERS-CoV) in 2012 and the current of SARS-CoV-2
outbreak, known as COVID-19 [1]. In 2002, SARS-CoV
originated in Guangdong province, China, spreading to
37 countries, and the subsequent global epidemic was
associated with 8096 cases and 774 deaths [2]. Ten years
later, the MERS-CoV spread to 27 countries, causing
2494 infected cases and 858 deaths worldwide [2, 3].
The novel coronavirus currently known as (2019-nCoV)
was identified in 2019 and is the third highly pathogenic
CoV detected, with a fatality rate varying across coun-
tries and ranges of age. In addition, the 2019-nCoV
transmissibility is higher, the 2019-nCoV mean R0 (R0 is
used to measure virus transmissibility) ranged from 3.3
to 5.5, and it appeared higher than that of SARS-CoV
(2–5) and MERS-CoV (2.7–3.9) [2–6]. An estimated 18,
142,718 people have been infected and 691,013 have
died from December 2019 to 04 August 2020, yielding a
fatality rate of 3.81% % worldwide [7].
HIV, TB and newly Emerging Infectious Diseases such
as Coronavirus epidemics are expected to overlap in
high HIV and TB burden countries. The intersecting
coronavirus, HIV and TB epidemics in countries with a
high burden of HIV and TB infections pose several pub-
lic health challenges. In fact, TB is the leading immune-
suppressing infection and the most common cause of
death among HIV-infected patients [8]. Worldwide,
there were 37.9 million [32.7 million–44.0 million]
people living with HIV and 1.7 million [1.4 million–2.3
million] people became newly infected with HIV at the
end of 2018 [9]. WHO reports that people living with
HIV are 20 times more likely to develop TB than their
counterparts [10]. It is estimated that 1.1 million people
worldwide live with TB and HIV, 80% of whom live in
sub-Saharan Africa [11]. Since the emergence of HIV,
TB incidence is increasing and causing a high mortality
rate among people living with HIV/AIDS over the last
ten years [12]. In the post-mortem, the overall preva-
lence of TB in adults and children was huge and
accounted for almost 40% of HIV-related facility-based
deaths in adults in resource-limited countries [13]. This
is greater than the WHO/UNAIDS estimate that overall
TB accounts for approximately 25% of HIV/AIDS re-
lated deaths worldwide [13]. How COVID-19 will mani-
fest itself in persons co-infected with HIV/TB is still
uncertain [14]. Populations infected with HIV and TB,
those with undiagnosed pulmonary TB (PTB), drug-
resistant tuberculosis or complex presentations such as
disseminated types and those who have only started PTB
treatment may be at elevated risk for severe responses if
they are infected with COVID-19 [14]. In the future,
lung lesions associated with COVID-19 may increase the
risk of PTB, which induces a true vicious circle of HIV-
TB-COVID-19 co-infection. TB incidence is also antici-
pated to increase in high burden HIV/TB countries
including sub-Saharan countries with high COVID-19
burden. While COVID-19 continues to spread across
the world, many areas face the risk of infection with
SARS-CoV-2 and the obstacles and challenges to sus-
taining the continuum of HIV and TB treatment in
high-burden HIV/TB countries are increasing [14]. Co-
infection SARS-CoV/HIV/TB was previously not a major
threats because SARS-CoV and MERS-CoV pandemics
did not occur in countries with high HIV/TB burden.
Since December 2019, COVID-19 is spreading very fast,
with the high HIV/TB burden countries not spared from
the pandemic and the number of new COVID-19 cases
is expected to rise in the next few months. The inter-
secting coronavirus, TB and HIV epidemics in sub-
Saharan African countries where HIV and TB have the
highest prevalence and incidence respectively, pose
many challenges from the point of view of COVID-19/
TB diagnostics, COVID-19/HIV/TB clinical manage-
ment and post COVID-19 epidemic TB incidence as
COVID-19 pulmonary fibrosis may rapidly increase TB
incidence [15].
In fact, the pathogenicity of COVID-19 could be accel-
erated in people living with HIV who have compromised
immunity [1]. Recent evidence has indicated a substan-
tial association between coronavirus-related Lower Re-
spiratory Tract Infections (LRTIs) and increased risk of
death in immune-compromised individuals [16, 17]. At
the same time, the depletion of CD4 T cells in HIV and
latent TB-infection disrupts the integrity and architec-
ture of TB granulomas in the lung, thus facilitating pro-
gression to active TB [18–20]. Similarly, TB promotes a
microenvironment that facilitates the replication of HIV-
1 via various mediators [21]. In fact, irreversible im-
provements in lung architecture after SARS-CoV and/or
TB play a significant role in both SARS-CoV and TB
pathogenesis. Nonetheless, severe SARS-CoV can induce
the development of rapid pulmonary fibrosis compared
with mild courses of SARS-CoV disease usually ad-
vanced to organize phase diffuse alveolar damage (DAD)
and eventual long-term deposition of fibrous tissue [15].
On the whole, SARS-CoV, HIV and TB co-infection
may have deleterious consequences in all stages of SARS,
HIV and TB because the triple pandemics are related in
the immuno-pathological phase, constituting a vicious
circle. A thorough understanding of the interactions
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between the three deadly pandemics is crucial. Review-
ing the statistics in relation to high burden HIV/TB
countries and recent World Health Organization data
on COVID-19 in Sub-Saharan Africa; the following
countries may expect an increased number of TB during
or post COVID-19: South Africa, Nigeria, Cameroon,
Kenya, Tanzania, Mozambique, Zambia, Zimbabwe and
Uganda. The distribution of estimated new HIV cases
(2018), new TB cases and relapses (2018) and COVID-
19 cases (04 August 2020) are respectively 240,000; 227,
999; 516,882 (South Africa), 130,000; 103,921; 44,129
(Nigeria), 23,000; 23,403; 17,718 (Cameroon), 46,000; 94,
534; 22,597 (Kenya), 72,000; 74,692; 509 (Tanzania), 150,
000; 92,381; 1973 (Mozambique), 48,000; 35,071; 6580
(Zambia), 38,000; 25,204; 4075 (Zimbabwe) and 53,000;
55,835; 1195(Uganda) [7, 10, 22]. The map was drawn to
illustrate the distribution of COVID-19, HIV and TB in
the nine high burden countries in Sub-Saharan African
(Fig. 1). The aim of this study was to review different
studies on SARS-CoV or MERS-CoV associated with
HIV/TB co-infection or TB only and understands the in-
teractions between HIV, TB and COVID-19 and its im-
plications on the burden of the COVID-19 among TB/
HIV patients, screening algorithm and management.
Methods
The protocol was accepted by the international pro-
spective register of systematic reviews (PROSPERO)
(identification number: CRD42020181457). We con-
ducted a systematic review of the literature to examine
SARS-CoV or MERS-CoV associated with HIV/TB or
TB co-infection. As we anticipated heterogeneity in the
literature, meta-analysis and descriptive analysis were
undertaken. Meta-analysis was based on random-effects
modeling using Review Manager 5.3 [23] and Meta-
Essentials [24] was also used to compute Egger’s regres-
sion and Begg and Mazumdar rank correlation test to
evaluate possible publication bias. The odds ratio (OR)
for COVID-19/HIV co-infection or COVID-19 in rela-
tion to TB exposure was used as the summary measure
of risk in these meta-analyses. Heterogeneity across in-
cluded studies was estimated by χ2 and I2. Forest plots
and relevant supporting statistics were examined. Meta-
analyses for subgroups (on the basis of COVID-19/HIV/
TB vs COVID-19/TB) were also undertaken to investi-
gate heterogeneity between the subsets. We also com-
puted the test of two proportions with STATA version
14 to compare SARS, MERS or COVID-19 disease sever-
ity compared to TB and/or HIV in descriptive analysis.
We utilized formal methods of literature search, selec-
tion of articles for inclusion, an abstraction of data and
quality assessment, and synthesis of results to review the
literature on to examine SARS-CoV or MERS-CoV or
COVID-19 associated with HIV/TB or TB co-infection.
Inclusion criteria
The inclusion criteria were studies published in English,
from January 2020 until July 2020 that established co-
occurrence of SARS-CoV, MERS-CoV, COVID-19 HIV
and TB. Study designs included case reports, case series
and observational studies (case-control, prospective and
retrospective cohorts). Studies reporting COVID-19/HIV
co-infection without screening PTB, those reporting
other outcomes, letters to the editor, theoretical and
Fig. 1 Distribution of COVID-19, HIV and TB in the nine high burden countries in Sub-Saharan African
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incomplete studies were excluded. The outcomes in-
clude TB occurrence (before, during or after SARS,
MERS or COVID-19), SARS, MERS or COVID-19 sever-
ity (mild, moderate, severe and critical stages) in case of
HIV/TB or TB co-infections, the mean time of COVID-
19 severe/critical stages occurrence and the recovery and
mortality rates.
Search strategy
We searched eligible studies from 01 January 2002 to 27
July 2020 through Medline (PubMed), Google Scholar,
Medrxiv and the Cochrane Library without any study
design, published in English. Additionally, the WHO
COVID-19 database [22] and Clinicaltrials.gov were also
used to search for ongoing and completed studies re-
lated to co-infection COVID-19/HIV/TB. The following
terms were used “SARS-CoV”, “MERS-CoV”, “COVID-
19”, “SARS-CoV-2” AND “pulmonary tuberculosis”,
“PTB”, “lung TB”, “TB” AND “HIV/TB co-infection”
AND “TB/SARS co-infection” AND “TB/MERS co-
infection” “TB/Covid-19 co-infection” AND “HIV/SARS
co-infection” AND “HIV/MERS co-infection” AND
“HIV/COVID-19 co-infection”. Relevant articles pub-
lished in English that resulted from the searches, and
references cited therein, were reviewed and duplicate
studies were removed. After removing duplicates, we
checked the title and abstract and reviewed full-text, in-
clusions and exclusions were recorded following PRIS
MA guidelines presented in the form of a PRISMA flow
diagram and detailed reasons recorded for exclusion.
Critical appraisal checklists appropriate to each study
design were applied and conducted in pairs (JTL and
PSN).
Data extraction
A customized data extraction form was designed and
piloted prior to data extraction. For each study included,
we collected the following information: authors and pub-
lication year, title and journal, study country, study de-
sign, sample size, participants characteristics such as age
and sex, the number of conditions included (SARS-CoV,
MERS-CoV, COVID-19, HIV and TB) and the outcomes
include TB occurrence (before, during or after SARS,
MERS or COVID-19), SARS, MERS or COVID-19 sever-
ity (mild, moderate, severe and critical stages) in case of
HIV/TB or TB co-infections, the average time of
COVID-19 severe/critical stages occurrence, and the re-
covery and mortality rates. The data extraction was con-
ducted in pair by (JLT and BTA). Conflict resolution
was conducted by a third co-author (PSN).
Assessment of study quality
Two reviewers (JTL and BTA) independently assessed
study quality based on the Newcastle-Ottawa scale
(NOS) [25]. The Newcastle-Ottawa scale assessed the se-
lection, comparability and exposure of a case-control
study and selection, comparability, and outcome of a co-
hort study. Nine stars reflect maximum ranking, and the
sample with over 6 stars was considered to be of reason-
ably high quality. Any questions about the content of
the included studies were determined in consultation
with another reviewer (PSN).
Results
Search results
Electronic search identified 532 articles. Inclusions and
exclusions were reported following PRISMA guidelines
presented in the form of a PRISMA flow diagram (Fig. 2)
with reasons for exclusion recorded (Table 1) as follows:
95 duplicates were removed; after reading the titles of
articles, 379 articles were removed. Among 58 records
screened, 21 full-text studies were assessed for eligibility.
Thirty-seven articles were excluded because there were
either incomplete or irrelevant articles. Twenty-one
studies were included for qualitative analysis, of which
five were case reports, eight case series, one case-control
and seven cohort studies (Table 2). Seven out of eight
observational studies were included in the meta-analysis.
One retrospective cohort was included in the descriptive
analysis because COVID-19/TB co-infected cases were
identified in both cases and exposed groups [47]. Each
article that met selection criteria was fundamentally
assessed for Author/Country, Population/Study design,
Exposures, Comparators, Treatments, TB occurrence
and SARS/MERS/COVID-19 severity, recovery and mor-
tality rate.
Table 2 presents a summary of 21 included studies.
The review included 28,387 COVID-19, 6 SARS-CoV
and 2 MERS-CoV participants with HIV/TB or TB.
Among them, 1294 were COVID-19/TB, 1094 COVID-
19/HIV/TB, 5 SARS-CoV/TB, 2 MERS-CoV/TB and 1
SARS-CoV/HIV/TB. Four cohort studies [41, 44, 45, 48],
one case control study [38] and four case series [28, 29,
34, 49] were conducted in China, two case series [30, 39]
were done in Singapore, one case series [32] and one
case control study [37] were undertaken in Saudi Arabia,
a case series [40] was conducted in Italy, one cohort
study was done in South Africa [42] and another in the
Philippines [43], one case study was conducted in the
United State of America [35], other three case studies
were found in Turkey [36], Hong Kong [31] and India
[33] respectively. Lastly, a retrospective cohort was
undertaken in eight countries (Italy, Belgium, Brazil,
France, Russia, Singapore, Spain, and Switzerland) [47].
Quality assessment of included studies
The methodological validity of included studies for de-
termining the consistency of case-control study and
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cohort studies in meta-analyses was based on the NOS
[25]. This method explores three major components:
range, comparability and exposure. The NOS uses a star
chart with ratings from 0 to 9 for case–control and co-
hort studies. Since the requirements for a study’s high or
low quality are not well known, we considered a study
with a higher score than the six of each form of study to
be a high-quality study. Among included studies, two
scored seven and high, three scored six and the other
two studies scored less than six and were therefore con-
sidered low quality. The NOS scores for the included
studies are shown in Table 1 (Supplementary material).
Descriptive analysis
Fourteen studies (one observational study, eight case
series and five case studies) were included in the de-
scriptive analysis. We identified 113 cases with SARS-
CoV, MERS-CoV or COVID-19 associated to HIV/TB
or TB. The computed median age between case studies
and case series was 32 years compared to the cohort
study median age of 70 years [47]. Males had higher
SARS-CoV or MERS-CoV or COVID-19 associated to
HIV/TB or TB co-infections than females with 70% (28/
40). Table 2 describes all cases. For further clarifications,
cases were grouped as follows:
Cases of SARS-CoV, MERS-CoV or COVID-19 with previous
history of PTB diagnosis
Six studies (an observational study, four case series and
one case study) [29, 32, 34, 37, 47, 49] included cases
known to have a history of PTB (sputum smear–negative
for acid-fast bacilli) and became infected with SARS-
CoV (two cases) or MERS-CoV (two cases) or COVID-
19 (eight cases). PTB diagnosis was made based on pre-
vious exposure to TB, relevant symptoms of typical PTB,
chest radiographs suggestive of active disease or IGRA
(Interferon Gamma Release Assay). SARS-CoV or
MERS-CoV was confirmed based on amplification of
SARS-CoV/MERS-CoV RNA by reverse transcriptase–
polymerase chain reaction (RT-PCR) from sputum.
SARS-CoV/TB co-infected cases were managed with
corticosteroids and anti TB drugs. Clinical management
was not specified for MERS-CoV/TB co-infected cases;
however anti TB drugs were administered. Lopinavir/r,
Fig. 2 Flow diagram of SARS-CoV or MERS-CoV or COVID-19 associated with TB/HIV or TB studies included in the review. Note. From
PRISMA: www.prisma-statement.org
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Table 1 Description of studies excluded in review
N Author/Country Population/Study design Reasons for exclusion
1 Shalhoub 2015
Saudi Arabia
A patient with MERS-CoV/HIV co-infection/case study TB status was not reported
2 Bogorodckaya 2020
Russia
three TB patients co-infected with COVID-19/ case study Cases were incompletely reported.
3 Wang 2020
China [26]
A patient with COVID-19/HIV co-infection/case report TB status was not reported
4 Zhu 2020
China
A patient with COVID-19/HIV co-infection/case report TB status was not reported
5 Zhao 2020
China
A patient with COVID-19/HIV/HCV co-infection/ case report TB status was not reported
6 Baluku 2020
Uganda
A patient with COVID-19/HIV co-infection /case report TB status was not reported
7 Blanco 2020
Spain
Five cases of COVID-19/HIV co-infection/ clinical case series None reported TB status
8 Riva 2020
Italy
Three cases with COVID-19/HIV co-infection / case series None reported TB status
9 Aydin 2020
Turkey
Three patients with COVID-19/HIV co-infection /case series Outcomes of interest were not reported
10 Benkovic 2020
USA
Four patients with COVID-19/HIV Co-infection/Case series Outcomes of interest were not reported
11 Haddad 2020
USA
A case with COVID-19/HIV co-infection/Case report TB screening was not reported
12 Gervasoni 2020
Italy
47 COVID-19/HIV co-infected patients Retrospective study Outcomes of interest were not reported
13 Wang 2020
China [26]
A patient with COVID-19/HIV Co-infection/Case report TB status was not reported
14 Härter 2020
Germany
33 COVID-19/HIV co-infected patients Retrospective study Outcomes of interest were not reported
15 Wu 2020
China
Two patients with COVID-19/HIV co-infection/Case series TB screening was not reported
16 Del 2020
Spain [27]
77,590 COVID/HIV co-infected cases Outcomes of interest were not reported
17 Bulled 2020
South Africa
Comment on COVID-19/HIV/TB co-infection This was a commentary
18 Tadolini 2020
Italy
49 patients with COVID-19/TB co-infection Duplicate report from the same cohort
19 Chen 2020
China [28]
COVID-19/TB burden Letter to the editor without case report
20 Drain 2020
USA
Explanatory article on COVID/HIV burden TB screening was not reported
21 Karim 2020
USA
Included percentage of COVID-19/HIV/TB report No primary data reported
22 Pang 2020
China
Included COVID-19/TB cases A correspondence
23 Wang 2020
China [26]
A case of COVID-19/HIV co-infection The outcomes of interest were not reported
24 Kilds 2020
USA
A case of COVID-19/HIV co-infection The outcomes of interest were not reported
25 Ridgway 2020
USA
A case series of five COVID-19/HIV co-infection Had no outcome of interest reported
26 Sigel 2020
USA
Eighty eight COVID-19/HIV co-infection Had no outcome of interest reported
27 Patel 2020
USA
A case study of COVID-19/HIV co-infection The interest outcome was not reported
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Arbidol, Ribavirin, corticoids (dexamethasone and me-
thyl prednisolone), prophylactic anticoagulation, empir-
ical antibiotics, traditional Chinese medicine and anti-
TB drugs were indicated to COVID-19/TB co-infected
cases. Eight out of fourteen had severe/critical disease
course among which one case of SARS-CoV, one of
MERS-CoV and six cases of COVID-19 and had a long
recovery process.
SARS-CoV or COVID-19 cases with PTB co-infection
Seven studies (an observational study, two case series
and four case studies) [29, 31, 33, 35, 36, 47, 49] diag-
nosed PTB (positive acid-fast bacilli smear on sputum
samples or IGRA), while cases were admitted for SARS-
CoV (two cases) and COVID-19 (twelve cases). SARS-
CoV and COVID-19 were confirmed by RT-PCR, and
microscopy as well as medical imaging diagnosed TB. A
case of SARS-CoV/HIV/TB co-infection [31] was man-
aged with abacavir/efavirenz/kaletra/tenofovir/ribavirin,
prednisolone and anti TB drugs and another case with
SARS-CoV/TB co-infection [29] was managed with
mechanical ventilation, corticosteroids and anti TB
drugs. All COVID-19/TB co-infected cases were man-
aged in the same way as for previous PTB/COVID-19
cases.
Cases of PTB with history of SARS-CoV
Two cases were diagnosed with PTB with positive bacilli
smear respectively four and two months after SARS-
CoV [30]. At day 80 of disease on convalescence, one of
the cases was positive for coronavirus IgG serum
antibody and the other case was positive for SARS cor-
onavirus by PCR of an endotracheal tube test, as well as
coronavirus IgM and IgG antibodies in the blood. Both
of them had severe COVID-19 before developing PTB.
Intravenous immunoglobulin and a short course of high-
dose corticosteroids were indicated during the SARS
course and anti TB drugs were administered during the
TB course. The said patients remained clinically stable
at follow-up.
Cases were stratified by PTB diagnosis. 41.36% (12/29)
of cases of SARS-CoV, MERS-CoV or COVID-19 had
previous history of PTB diagnosis. 74% of SARS-CoV or
COVID-19 Cases had PTB co-infection, and 6.89% (2/
29) of PTB had a history of SARS-CoV. The test of two
proportions between ‘severe/critical SARS, MERS and
COVID-19 cases with HIV/TB or TB co-infection 53%
(20/38)’ versus ‘mild/moderate SARS, MERS and
COVID-19 cases with HIV/TB or TB co-infection 47%
(18/38)’ was not statistically significant (P = 0. 6009).
The onset of COVID-19 severe/critical stages was mean
of 3.4 days [38] and a median of 9 days [47] for two ob-
servational studies and 10 days for a case series [34].
Three studies [28, 30, 32, 37, 39, 40, 47] reported the re-
covery and mortality rate among SARS, MERS and
COVID-19 cases with HIV/TB or TB co-infection which
were respectively 90.26% (102/113) and 9.74% (11/113).
The mortality rate of 9.74% among COVID-19/TB or
COVID/HIV/TB co-infected patients should be consid-
ered with caution because of poor study design and
small sample size. However, the mortality rates for
COVID-19/TB or COVID/HIV/TB co-infection seem to
Table 1 Description of studies excluded in review (Continued)
N Author/Country Population/Study design Reasons for exclusion
28 Guo 2020
China
A survey among COVID-19/HIV co-infected cases The interest outcome was not reported
29 Shalev 2020
USA
31 patients with COVID-19/HIV co-infection The outcomes of interest were not reported
30 Karmen-Tuohy 2020
USA
A case control of 21 patients COVID-19/HIV co-infection The outcomes of interest were not reported
31 Toombs 2020
United Kingdom
Three Cases with COVID-19/HIV co-infection Do not contain the outcome of interest
32 Ruan 2020
China
Three cases with COVID-19/HIV co-infection Had no outcome of interest reported
33 Sun 2020
Singapore
A case of SARS-2/HIV co-infection Had no outcome of interest reported
34 Richardson 2020
USA
43 cases of SARS-2/HIV co-infection Do not contain the outcome of interest
35 Ho 2020
USA
93 cases of SARS-s/HIV co-infection The outcomes of interest were not reported
36 Su 2020
China
Two cases with SARS-2/AIDS co-infection The outcomes of interest were not reported
37 Kumar
India
A case of COVID-19/HIV co-infection Had no outcome of interest reported
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be higher than the mortality rate of 3.81% for COVID-
19 worldwide [7]. Three studies [37, 38, 40] reported
COVID-19 recovery time from 9 to 54 days. This is im-
portant to highlight that qualitative analysis included
three cases related to SARS-CoV/HIV/TB co-infection
(one case) [31] and COVID-19/HIV/TB co-infection
(two cases) [28–30, 32, 34, 37–41, 44, 45, 47–49].
Among them, SARS-CoV/HIV/TB co-infected case de-
veloped mild disease course, one COVID-19/HIV/TB
developed severe COVID-19 and the last case died.
Meta-analysis
We included seven observational studies (six cohort
studies and one case control study) in the meta-analysis
(Fig. 2). A case control and four cohort studies were
conducted in China [38, 41, 44, 45, 48] and two other
cohort studies were undertaken in South Africa [42] and
the Philippines [43] (see Table 2). One cohort included
COVID-19/HIV/TB and COVID-19/TB co-infected
groups were included in the TB occurrence outcome,
with a total sample of 2015 participants. COVID-19 se-
verity included three cohort studies and one case control
for which the total sample size was 2074 participants. A
total of 22,838 and 23,017 participants were included in
recovery and mortality rates respectively. Each of them
included two and three cohort studies respectively. The
results of the meta-analysis based on seven observational
studies including HIV/TB or TB as exposures that may
impact on COVID-19 outcomes were described as
follows:
TB occurrence
This included previous and current TB occurrence
among COVID-19/HIV/TB and COVID-19/TB co-
infections. Only one study included TB occurrence [42].
Current TB showed a strong risk of COVID-19 among
HIV-infected cases OR 2.01 (95% CI 1.10–3.66), P = 0.02
compared to uninfected HIV cases OR 1.30 (95% CI
0.64–2.64), P = 0.47. TB occurrence pooled results be-
tween subgroup COVID-19/HIV/TB and COVID-19/TB
was OR 1.67(95%CI 1.06–2.65, P = 0.03). The test for
subgroup differences was not statistically significant with
I2 = 0%, P = 0.36 (Fig. 3).
COVID-19 severity
Three cohort studies [44, 45, 48] and one case control
studies [38] were included to compare mild/moderate
versus severe/critical COVID-19 stages in COVID-19/
TB co-infected patients. The pooled result revealed that
the COVID-19/TB group was at high risk of developing
severe/critical COVID-19 compared to the COVID-19
group OR 4.50 (95%CI 1.12–18.10, P = 0.03). The test of
heterogeneity was not statistically significant P = 0.16,
I2 = 42% (Fig. 4).
Recovery rate
Two cohort studies [42, 43] were included to evaluate
the recovery rate among the COVID-19/HIV/TB group
compared to the COVID-19/TB group. The subgroup
analysis was performed across the two groups. The
COVID-19/HIV/TB subset showed that COVID-19/HIV
co-infected group reached the highest odds in recovery
rate compared to the COVID-19/HIV/TB co-infected
group OR 2.63 (95%CI, 1.80–3.83, P < 0.00001). Simi-
larly, the COVID-19 group had the strongest odds of re-
covering compared to COVID-19/TB co-infected group
OR 2.09 (95%CI 1.65–2.66, P < 0.00001). The overall re-
sult showed that non-TB groups yielded an OR of 2.23
(95%CI 1.83–2.74, P < 0.00001) compared to TB in both
COVID-19/HIV and COVID-19 groups. The test for
subgroup differences was not statistically significant with
P = 0.32 and I2 = 0% (Fig. 5).
Mortality rate
Three observational studies [41–43] compared the mor-
tality rate among COVID-19/HIV/TB and COVID-19/
Fig. 3 Meta-analysis of TB occurrence among COVID-19/HIV/TB or COVID-19/TB co-infections. Outcome: TB occurrence
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TB co-infected groups. Subgroup analysis was under-
taken to evaluate the heterogeneity between the two
groups. Among those studies, Davies 2020 included both
COVID-19/HIV/TB and COVID-19/TB co-infected
cases. The first subgroup revealed that COVID-19/TB
co-infected group had a 74% risk reduction of dying
compared to the COVID-19/HIVTB co-infected group
(OR 0.36, 95%CI 0.25–0.52, P < 0.00001). In the same
way, the second subgroup analysis including two obser-
vational studies showed that the COVID-19 group had a
53% risk reduction of dying compared to the COVID-
19/TB co-infected group (OR 0.36, 95%CI 0.36–0.60).
The pooled results between non TB and TB in both sub-
groups revealed OR 0.43, 95%CI 0.35–0.53, P < 0.00001.
The test for subgroup difference showed no significant
heterogeneity across included studies P = 0.26, I2 = 21.1%
(Fig. 6).
Discussion
Reviewing descriptive analysis compared to meta-
analysis, meta-analysis illustrated that TB exposure is a
COVID-19 risk factor in point of fact TB occurrence,
COVID-19 severity, and recovery and mortality rates.
However, the descriptive analysis showed the interac-
tions between SARS-CoV, HIV and TB may occur dur-
ing SARS-CoV or after SARS-CoV. Men are more
vulnerable to SARS or MERS or COVID-19 associated
to HIV/TB or TB. It is highly likely that both previous
SARS-CoV with newly diagnosed PTB acquired active
PTB after contracting SARS. This is so because both had
laboratory-confirmed clinical syndromes associated with
SARS, and both recovered well without anti-TB treat-
ment, with initial biochemical and radiological improve-
ment [29]. The descriptive analysis of cases also found
that SARS-CoV could induce a transient suppression of
cellular immunity that further predisposed patients to
exacerbated reactivation or new TB infection, as is the
case with HIV. SARS-CoV and HIV may decrease con-
junctly CD4 count and lymphocytes, adding high corti-
costeroids [29] as a treatment for SARS-CoV may be TB
precipitant factors [29]. Following this, SARS-CoV or
COVID-19 patients may-be more susceptible to active
and latent TB as proven by different studies [29, 31, 33,
35, 36, 47]. It is important to realize that lung lesions
due to SARS and/or TB may increase significantly the
likelihood of SARS-CoV and TB. Lastly, the descriptive
analysis showed COVID-19 time-to-recovery in COVID-
19/TB co-infected cases may be longer and severe/crit-
ical COVID-19 symptoms may be precocious. An
observational study has showed a statistically significant
result in time-to-recovery (P = 0.0046) [43].
A meta-analysis assessing TB occurrence COVID-19/
HIV/TB versus COVID-19/TB co-infected cases demon-
strated that the risk of COVID-19 was high among
current TB/HIV co-infected cases in subgroup analysis.
HIV-infected people are more vulnerable to COVID-19.
Although we estimated the pooled COVID-19 rate and
the result showed that the COVID-19/TB group was at
Fig. 4 Meta-analysis of COVID-19 severity among COVID-19/TB co-infected patients. Outcome: COVID-19 severity
Fig. 5 Meta-analysis of COVID-19/HIV/TB versus COVID-19/TB co-infections. Outcome: recovery rate
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high risk of developing severe/critical COVID-19 com-
pared to the COVID-19 group. This needs careful inter-
pretation due to a wide overall 95% CI as well as due to
studies with different designs. This evidence is supported
by two large cohort studies conducted in Spain and
South Africa, showing that the risks for PCR-confirmed
COVID-19 diagnosis, hospitalization, Intensive Care
Unit (ICU) admission, and death among HIV-positive
persons receiving ART were greater in men compared to
old age [27, 31, 33, 35, 36, 42, 43]. However, the risk for
hospitalization varied by the nucleoside transcriptase
inhibitor (NRTI) regimen and was lower in patients
receiving TDF/FTC versus those receiving other regi-
mens [27, 31, 33, 35, 36, 42, 43].
Our results suggest that the recovery rates be-
tween COVID-19/HIV/TB and COVID-19/TB
groups were quite the same OR 2.63 (95%CI, 1.80–
3.83, P < 0.00001) and OR 2.09 (95%CI 1.65–2.66,
P < 0.00001) respectively. However, COVID-19 pa-
tients recovered faster than both COVID-19/HIV/
TB and OR 2.09 (95%CI 1.65–2.66, P < 0.00001).
This observation is supported by qualitative evi-
dence as shown above.
The poor outcome in mortality rate among COVID-
19/HIV/TB co-infection compared to COVID-19/TB
infection is illustrated in Fig. 6. Both those with
COVID-19/HIV/TB and COVID-19/TB co-infection
had increased mortality risk compared to COVID-19
participants. Given recent developments that have
shown the vulnerability of those ages 18–49 to
COVID-19 [50, 51], younger people living with HIV
(PLWH) may also be at heightened risk for mortality
due to COVID-19 complications. Such risk is predi-
cated on the fact that PLWH under the age of 50
years are both less likely to be diagnosed (and in ef-
fect more likely to be immunocompromised) and also
less likely to access and be retained in care, yielding
viral suppression of a mere 37% for those age 25–34
years [51, 52].
Our review had a number of important limitations,
the most important being that almost all included
studies were observational and the number of in-
cluded studies was limited. Nevertheless, heterogen-
eity was not statistically significant between studies in
different subgroup analyses and the Egger regression
and Begg and Mazumdar’s test for rank correlation
were not statistically significant with P = 0.684 and
1.00 respectively, showing that publication bias was
minimized.
As shown above, COVID-19/HIV/TB or COVID-19/
TB co-infections are a new medical field that needs
further attention and research in high burden HIV/
TB countries more specifically in sub-Saharan Africa
as the co-existence of those three pandemics may
imply vulnerability to COVID-19 infections and in-
crease TB occurrence. Clear diagnostic algorithms, ex-
ploration of drug–drug interactions and clinical
management should be addressed to improve COVID-
19/HIV/TB outcomes.
Review implications: TB, HIV and COVID-19
diagnostics and clinical management
Even though data are scarce, the analysis indicated
that COVID-19/HIV/TB or COVID-19/TB co-
infections may have poor treatment outcomes. This
may be worsened in case TB is not diagnosed and
treated early. Furthermore, COVID-19 can shadow TB
in HIV-infected people or vice versa. For this reason,
we suggest screening for both COVID-19 and TB in
HIV-infected people with COVID-19/TB symptoms
during the COVID-19 pandemic in countries with
high HIV/TB burden. HIV/COVID-19 co-infection re-
quires a simple algorithm and management to boost
TB outcomes.
Fig. 6 Meta-analysis of TB mortality among COVID-19/HIV/TB or COVID-19/TB co-infections. Outcome: TB mortality
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TB diagnosis in COVID-19/HIV co-infection
Suspected cases of COVID-19 and TB show similar fever
and/or respiratory symptoms (difficult respiration,
coughing, chest pain, etc.). COVID-19 RT-PCR should
be done in real-time for differential diagnosis of cases
with unknown respiratory syndromes such as PTB [53].
Due to poor outcomes among COVID-19/HIV/TB or
COVID-19/TB co-infections, we recommend COVID-19
real-time RT-PCR should be coupled with Xpert MTB/
RIF assay. In suspected HIV/TB co-infected patients,
Xpert MTB/RIF should be used first rather than trad-
itional microscopy, culture and drug susceptibility test-
ing (DST) [54]. Instead of collecting upper respiratory
tract specimens, lower respiratory tract specimens, such
as sputum, bronchoalveolar lavage, and tracheal aspi-
rates should be collected in suspected COVID-19/HIV/
TB or COVID-19/TB co-infected patients. COVID-19
real-time RT-PCR may last at least 24 h. At the same
time, the Xpert MTB / RIF assay detects M. tuberculosis
and rifampicin resistance within less than two hours
[55]. Xpert MTB/RIF is also a major advance in the
diagnosis of TB, particularly for multidrug-resistant
(MDR) TB and HIV-associated TB [54]. The Xpert
MTB/RIF assay’s sensitivity to detect TB is superior to
that of microscopy and comparable to that of solid cul-
ture, along with high specificity [55].
This is important to emphasize that possible causes of
false negative COVID-19 real-time RT-PCR results in
COVID-19/HIV co-infection may be identified in pa-
tients on protease inhibitors (PIs) based regimens. We
also recommend systematic TB screening in COVID-19/
HIV co-infection. The adapted algorithms to diagnose
TB in confirmed COVID-19/HIV co-infected adults in
high burden HIV/TB countries are described below:
Option 1: This algorithm includes an interrogatory
about cough of any duration, fever, short breathing, sore
throat, loss of weight, loss of appetite, nausea,
hemoptysis and night sweat. Past medical history in-
cludes previously confirmed TB, previous TB contact,
TB preventive therapies, unsuppressed HIV viral load
and CD4 count ≤350 cells/μL. Xpert MTB/RIF assay
should be indicated. If Xpert MTB/RIF assay is positive,
start anti TB drugs.
Option 2: This algorithm includes symptoms and med-
ical history of COVID-19, HIV and TB as described in
option 1. Xpert MTB/RIF assay should be indicated. If
Xpert MTB/RIF assay is negative, the culture associated
with the chest X-ray should be requested. If abnormal
chest X-ray suggestive of TB, start anti-TB drugs, in the
meantime while waiting for culture results.
Option 3: This algorithm includes symptoms and med-
ical history of COVID-19, HIV and TB as described in
option 1. If Xpert MTB/RIF assay is negative and the X-
ray is not suggestive of TB, the culture associated with
an approved interferon-gamma release assays (IGRAs)
should be performed. Current evidence indicates that
IGRAs perform similarly to the tuberculin skin test
(TST) at identifying HIV-infected individuals with TB
[56]. However, the decision to use either test should be
based on country guidelines and resource and logistical
considerations. If IGRAs is positive and the culture is
negative, start TB preventive treatment. Isoniazid mono-
therapy for six (6) months is recommended for the treat-
ment of LTBI in both in high burden HIV/TB countries
[57]. Rifampicin or rifapentine plus isoniazid daily for
three (3) months should be offered as an alternative to
six (6) months of isoniazid. However, rifampicin and
rifapentine should be prescribed with caution in HIV/
COVID-19 co-infection due to potential drug-drug
interactions.
Option 4: This algorithm includes a history of previous
COVID-19, previous contact or active TB, HIV positive,
HIV viral load and CD4 count. All people with cough of
any duration, fever, short breathing, sore throat, weight
loss, hemoptysis, night sweat, arthralgia or myalgia
should be investigated for TB. The Xpert MTB/RIF assay
coupled with COVID-19 IgG/IgM should be indicated.
A recent study has found that the specificities of serum
IgM and IgG to diagnose COVID-19 were both more
than 90% when compared to molecular detection [58]. If
the Xpert MTB/RIF assay is negative, see options 2 and
3.
Clinical management
Drug-drug interactions and clinical considerations
In the case of concurrent HIV and tuberculosis infection
plus SARS-CoV-2 infection, the additional drug might
cause interaction complicating the integrated therapy. In
fact, some pharmaceutical interventions found for
COVID-19 treatment including Protease inhibitors (PIs)
(atazanavir, lopinavir, ritonavir, daranavir, raltegravir,
cobicistat), remdesivir, ribavirin, arbidol, chloroquine,
hydroxychloroquine, methylprednisolone, dexametha-
sone, anticoagulants and carrimycin may interfere and
interact with TB and/or HIV treatments in multiple
ways. Although protease inhibitors (PIs) were developed
to be selective inhibitors of HIV-1 replication, they have
shown inhibitory activity against a wide variety of patho-
gens [58], including SARS-CoV. Lopinavir / ritonavir
(LPV/r) has a moderate anti-SARS-CoV-2 antiviral activ-
ity which works against the 3CL protease virus [59, 60].
A recent systematic review concluded that it is unclear
whether LPV/r and other ART enhance clinical out-
comes in severe symptomatic disease or prevent infec-
tion in patients at high- risk of COVID-19 based on the
evidence available [61], as most of the studies included
were case studies and also observational studies were
low of power. Drug-drug interactions between PIs and
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rifampicin are known in HIV/TB co-infection. Studies
have demonstrated that co-administration of PIs with ri-
fampicin reduces PIs systemic concentration to less than
75% (cytochrome P 450 induction) [62, 63]. This may
compromise COVID-19 treatment. Remdesivir should
also not associate to rifampicin in COVID-19/TB co-
infection because of strong induction [64]. A recent re-
view has reported that chloroquine phosphate and
hydroxychloroquine showed favorable outcomes in the
recovery of COVID-19 patients [26, 65–68]. Both
chloroquine and hydroxychloroquine are metabolized by
hepatic cytochrome P450 enzyme 2D6 (CYP2D6) [69].
The most frequently involved in drug interactions are
CYP3A4 and CYP2D6 [70]. The reduction in the efficacy
of chloroquine when administered in conjunction with
rifampicin may be due to the inducing effect of rifampi-
cin on multidrug resistance associated protein (MRP)
and development of CYP450 [70]. Additionally, high-
dose chloroquine is more toxic than lower dose [64].
This is why; studies should clarify chloroquine and
hydroxychloroquine dose adjustment in COVID-19/TB
co-infection. Based on the above, dose adjustments
should be taken into consideration in case PIs, chloro-
quine, hydroxychloroquine and remdesivir are adminis-
tered with rifampicin. Another option is to shift
rifampicin to rifabutin or adapted TB regimens without
rifampicin. In contrast, clofazimine used in MDR-TB is
a strong inhibitor of PIs, known substrates [71]. Then,
caution should be taken when administered with PIs.
Another TB drug with in vitro effect used in COVID-19
is carrimycin. Its use in COVID-19 may mitigate active
TB and biases the TB diagnostic.
A study showed an association between corticosteroid
use and lower mortality in COVID-19 patients [68].
Using a glucocorticoid in the early stages of the progno-
sis for a brief period of time could minimize the inflam-
mation, but longer-term use could result in the risk of
HIV and/or TB activation and even lack of treatment
with TB. Careful use of corticosteroids with low-to-
moderate doses in short courses is advised [68]. Besides,
fibrosis and extensive pulmonary pathology secondary to
TB and COVID-19, as defined in the introduction, can
reduce drug penetration at the lung sites. It is a signifi-
cant risk factor for bad TB outcomes in the event of po-
tential infection or reactivation of TB [72]. This may
also induce MDR-TB or extensively drug-resistant tuber-
culosis (XDR-TB) or recurrent pneumonia. Then, special
considerations should be taken into account in the clin-
ical management of COVID-19/TB lung fibrosis. Some
RCTs are currently underway evaluating the safety and
effectiveness of antifibrotic therapies on COVID-19 lung
fibrosis [46].
Besides, liver and kidneys toxicities related to severe
and critical COVID-19 need a tailored therapeutic
approaches in HIV/TB co-morbidities due to some hep-
atotoxicity and nephrotoxicity of some HIV/TB drugs
such as streptomycin, isoniazid, rifampicin, pyrazina-
mide, tenofovir disoproxil, atazanavir/ritonavir, lopina-
vir/ritonavir as well as HIV induced nephropathy and
hepatitis associated to HIV.
Clinical management approach
1. Mild to Moderate COVID-19 associated with HIV/
TB co-infection: Hospitalized in a special unit named
COVID-19/TB units as risk patients. Start COVID-19
antiviral drugs, start or continue anti TB drugs ac-
cording to the national guidelines and continue ART.
Preferred COVID-19 antivirals are oseltamivir, chloro-
quine or hydroxychloroquine associated to LV/r or
darunavir/cobicistat and Azithromycin may be indi-
cated [68]. Chloroquine: 1 g PO once on Day 1, then
500 mg PO once daily for 4–7 days, hydroxychloro-
quine: 800 mg PO once on Day 1, then 400 mg PO
once daily for 4–7 days [64] or lopinavir 400 mg/rito-
navir 100 mg PO twice [65]. All of them should be
associated with Azithromycin [64]. Drugs interactions
should be reviewed as described above. Initial evalu-
ation includes a chest x-ray, complete blood count
(CBC), liver transaminases, renal function, inflamma-
tory markers such as C-reactive protein (CRP), D-
dimer, and ferritin, while not part of standard care,
may have prognostic value.
2. Severe COVID-19 associated to HIV/TB co-infection:
Hospitalized in COVID-19/TB unit as high-risk patients.
Drug therapy and ventilator support are milestones. Clini-
cians can refer to COVID-19 antiviral therapy and
immune-based therapy [64]. Start COVID-19 antiviral
drugs as described in mild to moderate COVID-19, add
immune-based therapy, initiate or continue anti TB drugs
according to national guidelines and nephrotoxic ART regi-
mens may be discontinued, switched to another ART regi-
men or adjusted dose based on the kidney function and
drug-drug interactions [73]. Remdesivir is recommended in
severe/critical COVID-19 however this cannot be adminis-
tered with rifampicin [64]. Short period low-dose cortico-
steroid therapy is preferred over no corticosteroid therapy
in HIV/TB co-infection and also the patients are in the in-
tensive care unit [64]. Anticoagulant therapy mainly with
low molecular weight heparin should be initiated early as
this appears to be associated with better prognosis in severe
COVID-19 patients [74]. Ventilator support, oxygen
through a face mask and symptomatic therapy should be
indicated. Initial evaluation includes chest x-ray/CT-scan
and CBC should be indicated. Liver transaminases and
renal function should be monitored regularly in consider-
ation of COVID-19/HIV/TB drug-drug interactions and
clinical considerations. Measurements of inflammatory
markers, D-dimer, and ferritin are part of the management.
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3. Critical COVID-19 associated to HIV/TB co-
infection: Hospitalized in COVID-19/TB unit with ICU
as high-risk patients. Infection control and testing, venti-
lator support, hemodynamic, and drug therapy are mile-
stones [65]. Apply COVID-19, TB and HIV management
as described in severe COVID-19. Short period low-dose
corticosteroid therapy, anticoagulant therapy and nor-
epinephrine as the first-choice vasopressor are recom-
mended [64]. Anticoagulant therapy mainly with low
molecular weight heparin appears to be associated with
better prognosis in severe/critical COVID-19 patients
with markedly elevated D-dimer [74]. There is strong
evidence against the use of hydroxyethyl starches for the
acute reanimation of adults with COVID-19 in shock
[75]. In adults with COVID-19 in shock, if the peripheral
oxygen saturation (SpO2) is < 92%, the review suggested
starting supplemental oxygen if SpO2 is < 90% [75]. Ini-
tial evaluation includes chest x-ray/CT-scan and CBC
should be indicated. Liver transaminases and renal func-
tion should be monitored regularly in consideration of
COVID-19-HIV and TB drug-drug interactions and clin-
ical considerations. Inflammatory markers, D-dimer, car-
diac enzymes and ferritin monitoring should be part of
the management.
4. Previous history of COVID-19 in HIV/TB co-
infection: This group of cases should be treated as HIV/
TB co-infection as described in different national guide-
lines. Therefore, emphasis should be put on the risk of
severe lung fibrosis that may induce MDR-TB or XDR-
TB. Ongoing trials are evaluating the safety and effect-
iveness of antifibrotic therapy in COVID-19 severe and
critical patients [46]. This could be beneficial in COVID-
19-HIV and TB co-infected cases due to their synergic
roles in inducing pulmonary fibrosis.
Conclusion
This is the first systematic review of the burden of
COVID-19-HIV and TB co-infection in high burden
HIV/TB countries. This review highlighted special con-
siderations that should be taken in high burden HIV and
TB countries at present and in the future. The results of
the present descriptive analysis and meta-analysis of
twenty one studies among which two were four case re-
ports, eight case series, one case-control and eight co-
hort studies. Descriptive analysis has shown that SARS-
CoV, MERS-CoV and COVID-19 associated with HIV/
TB or TB are more common in males and the time-to-
recovery is long compared to the non-exposure groups.
Meta-analysis suggests that HIV/TB co-infection or TB
exposures increase the risk of severe/critical COVID-19
and the mortality. The current TB group has an in-
creased risk of COVID-19 compared to the previous TB.
Additionally, the HIV/TB co-infected group has the
highest risk in the COVID-19 mortality rate and poor
recovery rate. This evidence is strong enough as substan-
tial heterogeneities were absent in all the results (I2
values were less than 50% in all the meta-analysis).
Based on the results, the review offers special attention
on diagnostics and management of COVID-19/HIV/TB
and COVID-19/TB co-infections. TB diagnostic suggests
four algorithms fast-tracking TB investigations in
COVID-19/HIV/TB and COVID-19/TB co-infections.
Well-structured clinical management has been sug-
gested, focusing on COVID-19, HIV and TB drug-drug
interactions and also COVID-19 clinical considerations.
Knowing that COVID-19 and TB may induce the de-
velopment of severe lung disease leading to pulmonary
fibrosis in the future, further studies are needed with co-
horts of HIV/COVID-19 co-infected individuals. More
research is needed to explore the effect of lung fibrosis
related to COVID-19 in high burden HIV/TB countries.
This pressing priority will shed light on the utility of
prophylaxis treatments in preventing post-COVID-19
related LRTIs in high burden HIV/TB countries.
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